Go Pro
→ Shocking new footage just released (From Digest Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Comera Life Sciences Holdings, Inc. stock logo
CMRA
Comera Life Sciences
$0.00
+∞		$0.00
$0.00
▼
$0.00
$3K1.058,113 shs31,500 shs
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
$0.00
$0.00
▼
$0.05
$10K1.767,146 shsN/A
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
$0.00
$0.00
$0.00
▼
$0.02
$11K1.3115,534 shs30,100 shs
Trevena, Inc. stock logo
TRVN
Trevena
$0.01
$0.00
$0.00
▼
$1.50
$11K-0.55726 shs44 shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Comera Life Sciences Holdings, Inc. stock logo
CMRA
Comera Life Sciences
0.00%0.00%0.00%0.00%0.00%
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
0.00%0.00%0.00%0.00%+100.00%
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
0.00%0.00%+300.00%+300.00%+300.00%
Trevena, Inc. stock logo
TRVN
Trevena
0.00%+2,700.00%+1,020.00%+646.67%+12.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Comera Life Sciences Holdings, Inc. stock logo
CMRA
Comera Life Sciences
$0.00
+∞		$0.00
$0.00
▼
$0.00
$3K1.058,113 shs31,500 shs
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
$0.00
$0.00
▼
$0.05
$10K1.767,146 shsN/A
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
$0.00
$0.00
$0.00
▼
$0.02
$11K1.3115,534 shs30,100 shs
Trevena, Inc. stock logo
TRVN
Trevena
$0.01
$0.00
$0.00
▼
$1.50
$11K-0.55726 shs44 shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Comera Life Sciences Holdings, Inc. stock logo
CMRA
Comera Life Sciences
0.00%0.00%0.00%0.00%0.00%
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
0.00%0.00%0.00%0.00%+100.00%
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
0.00%0.00%+300.00%+300.00%+300.00%
Trevena, Inc. stock logo
TRVN
Trevena
0.00%+2,700.00%+1,020.00%+646.67%+12.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Comera Life Sciences Holdings, Inc. stock logo
CMRA
Comera Life Sciences
0.00
N/AN/AN/A
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
0.00
N/AN/AN/A
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
0.00
N/AN/AN/A
Trevena, Inc. stock logo
TRVN
Trevena
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Comera Life Sciences Holdings, Inc. stock logo
CMRA
Comera Life Sciences
$1.00M0.00N/AN/AN/A∞
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
$8.13K0.00N/AN/AN/ANaN
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
$386K0.03N/AN/A$0.79 per share0.00
Trevena, Inc. stock logo
TRVN
Trevena
$443K0.02N/AN/A($11.07) per share0.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Comera Life Sciences Holdings, Inc. stock logo
CMRA
Comera Life Sciences
-$18M-$0.18N/AN/AN/AN/AN/AN/AN/A
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
-$15.18M-$0.21N/AN/AN/AN/AN/AN/AN/A
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
-$164.57M-$3.03N/AN/AN/AN/A-3,369.56%-97.04%10/29/2026 (Estimated)
Trevena, Inc. stock logo
TRVN
Trevena
-$40.29M-$47.04N/AN/AN/AN/AN/A-119.55%11/5/2026 (Estimated)
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Comera Life Sciences Holdings, Inc. stock logo
CMRA
Comera Life Sciences
N/AN/AN/AN/AN/A
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
N/AN/AN/AN/AN/A
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
N/AN/AN/AN/AN/A
Trevena, Inc. stock logo
TRVN
Trevena
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Comera Life Sciences Holdings, Inc. stock logo
CMRA
Comera Life Sciences
N/AN/AN/A
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
N/AN/AN/A
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
N/A
2.25
2.25
Trevena, Inc. stock logo
TRVN
Trevena
N/A
2.42
2.42

Institutional Ownership

CompanyInstitutional Ownership
Comera Life Sciences Holdings, Inc. stock logo
CMRA
Comera Life Sciences
N/A
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
0.01%
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
91.47%
Trevena, Inc. stock logo
TRVN
Trevena
13.56%

Insider Ownership

CompanyInsider Ownership
Comera Life Sciences Holdings, Inc. stock logo
CMRA
Comera Life Sciences
8.90%
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
43.68%
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
12.26%
Trevena, Inc. stock logo
TRVN
Trevena
2.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Comera Life Sciences Holdings, Inc. stock logo
CMRA
Comera Life Sciences
230.74 million28.00 millionNot Optionable
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
10100.08 million56.37 millionNo Data
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
6826.83 million23.54 millionNo Data
Trevena, Inc. stock logo
TRVN
Trevena
23959,000841,000No Data

Recent News About These Companies

Trevena stock holds near its yearly range as trading data reset
September 22 at 9:00 AM  |  ad-hoc-news.deA
Trevena (NASDAQ:TRVN) Share Price Passes Below 200-Day Moving Average - Should You Sell?
September 18, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31029997
Trevena Inc.
May 27, 2026  |  marketwatch.comhttps://www.marketwatch.com/investing/stock/TRVN/financials
Trevena Restructures China Royalty Rights to Exit Debt
January 14, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/trevena-restructures-china-royalty-rights-to-exit-debt?utm_source=marketbeat.com&utm_medium=referral
Softball: Conrad Weiser’s Alex Trevena earns statewide player of the year award; 5 other Berks players honored
July 8, 2025  |  msn.comhttps://www.msn.com/en-us/sports/mlb/softball-conrad-weiser-s-alex-trevena-earns-statewide-player-of-the-year-award-5-other-berks-players-honored/ar-AA1IcIZz
Trevena, Inc. (TRVN) - Yahoo Finance
June 29, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/quote/TRVN/press-releases/
Trevena Enters Securities Exchange Agreement with Investor
May 15, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/trevena-enters-securities-exchange-agreement-with-investor?utm_source=marketbeat.com&utm_medium=referral
Berks sports roundup: Alex Trevena helps Conrad Weiser to 8-5 softball win
April 11, 2025  |  readingeagle.comR
Vanessa Hudgens and Oliver Trevena Appear at Expo West for Caliwater
March 9, 2025  |  msn.comhttps://www.msn.com/en-us/music/news/vanessa-hudgens-and-oliver-trevena-appear-at-expo-west-for-caliwater/ar-AA1Axb5h
JMP Securities downgrades Trevena (TRVN) to a Hold
December 27, 2024  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/jmp-securities-downgrades-trevena-trvn-to-a-hold-1034177267
‘Plane’ Actor Oliver Trevena Signs With Untitled Entertainment
December 16, 2024  |  yahoo.comhttps://www.yahoo.com/entertainment/plane-actor-oliver-trevena-signs-153000870.html
Lyme Regis town councillor John Trevena stand down
December 11, 2024  |  bridportnews.co.ukB
Trevena (TRVN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
December 10, 2024  |  zacks.comhttps://www.zacks.com/stock/news/2381592/trevena-trvn-could-find-a-support-soon-here-s-why-you-should-buy-the-stock-now?cid=cs-stocknewsapi-ft-tale_of_the_tape|hammer_chart_pattern_(ta)-2381592
Trevena appoints new financial chief
November 29, 2024  |  investing.comhttps://www.investing.com/news/sec-filings/trevena-appoints-new-financial-chief-93CH-3745129
Trevena Appoints Katrine Sutton as New CFO
November 27, 2024  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/trevena-appoints-katrine-sutton-as-new-cfo?utm_source=marketbeat.com&utm_medium=referral
HC Wainwright & Co. Downgrades Trevena (TRVN)
November 16, 2024  |  msn.comhttps://www.msn.com/en-us/money/topstocks/hc-wainwright-co-downgrades-trevena-trvn/ar-AA1u9FYi
Trevena, Inc. Navigates Financial Challenges and Strategic Changes
November 9, 2024  |  msn.comhttps://www.msn.com/en-us/money/companies/trevena-inc-navigates-financial-challenges-and-strategic-changes/ar-AA1tMJqv
Chester County biopharm firm's latest layoffs impact its C-suite
November 7, 2024  |  bizjournals.comhttps://www.bizjournals.com/philadelphia/news/2024/11/07/trevena-chesterbrook-layoffs-c-suite-pain-medicine.html
Trevena teeters in dangerous territory, terminating CEO and other execs amid strategic review
November 7, 2024  |  fiercebiotech.comF
Trevena Reports Third Quarter 2024 Results and Provides Business Update
November 7, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/11/07/2976530/0/en/trevena-reports-third-quarter-2024-results-and-provides-business-update.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Comera Life Sciences stock logo

Comera Life Sciences NASDAQ:CMRA

$0.0001 +0.00 (+∞)
As of 12:13 PM Eastern

Comera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform. Its SQore platform is designed to enable the conversion of intravenous biologics to subcutaneous versions. The company's lead pipeline candidate is CLS-001, a subcutaneous formulation of vedolizumab for the treatment of inflammatory bowel disease, including Crohn's disease and ulcerative colitis. Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.

Navidea Biopharmaceuticals stock logo

Navidea Biopharmaceuticals NYSE:NAVB

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints. The company is also developing Tc99m tilmanocept for cardiovascular, kaposi's sarcoma, tuberculosis, and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.

Syros Pharmaceuticals stock logo

Syros Pharmaceuticals NASDAQ:SYRS

$0.0004 0.00 (0.00%)
As of 03:37 PM Eastern

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.

Trevena stock logo

Trevena NASDAQ:TRVN

$0.01 0.00 (0.00%)
As of 09/23/2026

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas